The Board of Directors of Jiangsu Hengrui Medicine Co., Ltd. has authorized a buyback plan on March 13, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
47.28 CNY | +0.32% | +8.44% | +4.53% |
05:23am | Hengrui Pharma Gets Green Light to Trial Four Cancer Drugs | MT |
Mar. 15 | Nomura Adjusts Jiangsu Hengrui Medicine’s Price Target to 51.12 Yuan From 49.24 Yuan, Keeps at Neutral | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.53% | 41.77B | |
+30.83% | 687B | |
+30.96% | 595B | |
+0.01% | 378B | |
+15.18% | 316B | |
+11.39% | 308B | |
+0.78% | 211B | |
-6.09% | 208B | |
-2.92% | 203B | |
-3.72% | 157B |
- Stock
- Equities
- Stock Jiangsu Hengrui Medicine Co., Ltd. - Shanghai S.E.
- News Jiangsu Hengrui Medicine Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd. authorizes a Buyback Plan.